New painkiller may reduce opioid use after skin graft surgery

NCT ID NCT03854344

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a long-acting numbing drug called liposomal bupivacaine (Exparel) can reduce pain and opioid use after skin graft harvesting in burn patients. 74 adults with small burns received either Exparel, lidocaine, or a nerve block. Researchers measured pain scores and how much opioid pain medication they needed in the first 72 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Liposomal bupivacaine (Exparel)
What this could lead to
If it works, this could provide better pain control and reduce opioid use after skin graft surgery.
What could go wrong
This is a small, completed Phase 4 study with only 74 participants. Results may not apply to all burn patients, and the pain relief may not be significantly better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BURNS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

burn Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Kansas Health System

    Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.